SecBot SecBot

UNCY

Unicycive Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001766140 Biotech & Drug Discovery
$3.58 −0.31 (−7.97%)
Oct 26 4:00 PM ET · prev $3.89
Market cap
$109.7M
Micro cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$27.50
+668% · range $13.00–42.00
Next earnings
Nov 18
in 23 days · EPS est. −$0.35
1 year
−31.7%
from $5.24 · Oct 27
30 days
−22.8%
from $4.64
52-week range
$3.36–8.56
−58% from high · low Oct 16
Avg volume 20D
1.13M
shares / day
Short interest
4.85M
≈17.4% of shares · +15.5%
Days to cover
5.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Unicycive Therapeutics resubmitted its NDA for oxylanthanum carbonate (OLC) to the FDA on September 29…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 13 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.364 → −$0.351 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +15.5% to 4.85M shares. 5.7 days to cover, ≈17.4% of shares.

  • TrendDOWNTREND

    24% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,413,381$6.6M
VANGUARD CAPITAL MANAGEMENT LLCADD1,071,481$5.0M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED564,019$2.6M
MARSHALL WACE, LLPDOUBLED547,862$2.6M
STATE STREET CORPDOUBLED450,162$2.1M
MILLENNIUM MANAGEMENT LLCNEAR_EXIT271,456$1.3M
CITIGROUP INCDOUBLED182,654$856.6K
NORTHERN TRUST CORPDOUBLED181,930$853.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy3Buy12Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +668%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 29, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 20, 2026Benchmark
MAINTAIN
MAINTAINSpeculative Buy
Aug 13, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 13, 2026B. Riley Securities
REITERATE
REITERATEBuy
Jul 1, 2026Benchmark
MAINTAIN
MAINTAINSpeculative Buy
Jul 1, 2026Noble Capital Markets
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 14, 2026
Gupta Shalabh K.
CEO
AWARD762,200 sh
May 14, 2026
Gupta Pramod
EVP, Pharmaceuticals and BD
AWARD169,500 sh
May 14, 2026
Townsend John
CFO
AWARD169,500 sh
May 14, 2026
Jermasek Douglas
EVP, Corporate Strategy
AWARD169,500 sh
May 14, 2026
Kenkare-Mitra Sara
Director
AWARD84,200 sh
May 14, 2026
Laumas Sandeep
Director
AWARD84,200 sh
May 14, 2026
Kenkare-Mitra Sara
Director
AWARD42,100 sh
May 14, 2026
Laumas Sandeep
Director
AWARD42,100 sh

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.35
EPS estimate, this quarter
+3%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.35-$0.66–-$0.23+0.3%$0.00
Next Q-$0.32-$0.43–-$0.16+1.0%$366.7K
Current FY-$1.27-$1.61–-$0.62-3.0%$1.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
4,854,102
shares short
+15.5%
vs prior settlement
5.7
days to cover
≈17.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 24, 2026 Other
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remi
Oct 1, 2026 SEC
Meredith Manning filed a Form 3 initial statement of beneficial ownership with Unicycive Therapeutics, reporting no…
3 — Impact 2/10
Sep 29, 2026 SEC
Unicycive Therapeutics resubmitted its NDA for oxylanthanum carbonate (OLC) to the FDA on September 29, 2026, using a…
8-K — Impact 7/10
Aug 12, 2026 SEC
Unicycive Therapeutics reported Q2 2026 results with a net loss of $(1.7) million ($(0.06)/share), significantly…
8-K — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,413,381 shares ($6.6M)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
1,071,481 shares ($5.0M)
May 14, 2026 Insider
Gupta Shalabh K. was granted 762,200 shares
CEO
May 14, 2026 Insider
Gupta Pramod was granted 169,500 shares
EVP, Pharmaceuticals and BD
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
UNCY Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Oct 24, 2026
Press release
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive…
Oct 21, 2026
M&A
Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit
SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of…
Oct 20, 2026
Press release
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shareholders should email [email protected] NEW YORK, Oct. 20, 2026 /PRNewswire/ -- What is the…
Oct 13, 2026
Press release
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 13, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive…
Oct 1, 2026
Press release
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a…

SecBot reports

10 filings · 1 press release · 1 bullish · 3 bearish · 1 mixed · 5 neutral
All UNCY filing & press-release reports (11)